Barclays
PLRX icon

Barclays’s Pliant Therapeutics PLRX Stock Holding History

Barclays’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-30,000
Closed -$336K – 5426
2024
Q3 		$336K Buy
+30,000
New +$375K ﹤0.01% 4017

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Barclays's PLRX Position: Q1 2026 in Review

Barclays reduced its Pliant Therapeutics (PLRX) stake by 100% in Q1 2026, selling an estimated $13.3K and leaving 34 shares worth $43. The position accounts for ﹤0.01% of the portfolio, ranked #4968.

Barclays first reported a position in PLRX in Q1 2022 and has held it in 17 quarters since. The position peaked at $6.39M in Q4 2023. 91 funds tracked by Wall St. Rank hold PLRX as of Q1 2026.

  • Barclays held 34 shares of Pliant Therapeutics worth $43 as of Q1 2026.
  • Barclays sold 10,550 Pliant Therapeutics shares in Q1 2026, an estimated $13.3K.
  • Pliant Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4968 holding.
  • Barclays first reported a position in Pliant Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Pliant Therapeutics position peaked at $6.39M in Q4 2023.
  • 91 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.